The biotechnology company Amgen was founded in 1980 as AMGen. With approximately 20,000 employees, Amgen is one of the world's largest biotechnology companies with annual sales of approximately $ 24 billion in 2018.
P/E ratio for Amgen (AMGN)
P/E ratio as of March 2023 (TTM): 19.8
According to Amgen's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 19.789. At the end of 2021 the company had a P/E ratio of 21.7.
P/E ratio history for Amgen from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 21.7 | 17.02% |
| 2020 | 18.6 | -0.31% |
| 2019 | 18.6 | 21.35% |
| 2018 | 15.3 | -76.8% |
| 2017 | 66.1 | 366.71% |
| 2016 | 14.2 | -20.05% |
| 2015 | 17.7 | -24.46% |
| 2014 | 23.5 | 38.6% |
| 2013 | 16.9 | 9.96% |
| 2012 | 15.4 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 22.4 | 13.44% | 🇺🇸 USA |
 Pfizer PFE | 7.19 | -63.68% | 🇺🇸 USA |
 AbbVie ABBV | 23.6 | 19.26% | 🇺🇸 USA |
 Eli Lilly LLY | 50.0 | 152.90% | 🇺🇸 USA |
 Biogen BIIB | 13.1 | -34.03% | 🇺🇸 USA |
 Gilead Sciences GILD | 22.1 | 11.93% | 🇺🇸 USA |
 Illumina ILMN | -7.93 | -140.07% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 25.1 | 26.67% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 4.43 | -77.59% | 🇬🇧 UK |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.